PublizoomAward notice Supplies
Eltrombopag
Notice published in Dutch. The AI analysis summarises it for you in your language.
- Public buyer
- VITAZ vzw
Sint-Niklaas - Place of performance
- 9100 Sint-Niklaas, East Flanders
- Amount awarded
- €2,000,000 excl. VAT
- Planned end of contract
- 30 April 2030
likely re-tender around October 2029 - Bids received
- 1
- Form
- Framework agreement
Multi-year contract: the buyer places orders as needs arise. - Procedure
- oth-single
- Publication
- 11 June 2026
- Notice language
- Dutch
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
Deze opdracht betreft het afsluiten van een raamovereenkomst met één opdrachtnemer waarbij alle voorwaarden voor de uitvoering van deze opdracht worden vastgelegd. Het doel van de raamovereenkomst is de levering van geneesmiddelen door de opdrachtnemer op afroep van de aanbesteder gedurende de looptijd beschreven in het bestek. Voor verdere toelichting verwijzen wij naar de technische bepalingen van het bestek.
Awarded to
- ACCORD HEALTHCARE BCE/KBO 0841.940.204
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33690000
Winning prices for comparable contracts
- A quarter below
- €444,216
- Median
- €606,904
- A quarter above
- €1,514,536
Amounts awarded (excl. VAT) over the last 3 years for 27 contracts in the same CPV group (3369…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
| Contract | Winner | Amount |
|---|---|---|
| Luspatercept VITAZ vzw · 22 October 2026 |
Orifarm Belgium | €3,000,000 |
| Ondansetron VITAZ vzw · 29 September 2026 |
Fresenius Kabi | €288,000 |
| Methotrexaat VITAZ vzw · 16 September 2026 |
Pharmanovia Benelux B.V. | €754,717 |
| Nintedanib VITAZ vzw · 17 July 2026 |
EG | €4,084,000 |
| Epoëtine Alfa VITAZ vzw · 4 June 2026 |
Sandoz NV | €1,920,000 |
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 401334-2026.